Loading…
EyePoint, Inc. is projected to rise to $15.86 by 2027, a +8% move from its current price of $14.72. EYPT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $14.26 | $14.72 | $15.19 | -0.02% |
| Jul 14 | $14.07 | $14.71 | $15.39 | -0.05% |
| Jul 15 | $13.92 | $14.71 | $15.54 | -0.07% |
| Jul 16 | $13.80 | $14.71 | $15.67 | -0.10% |
| Jul 17 | $13.69 | $14.70 | $15.78 | -0.12% |
| Jul 18 | $13.60 | $14.70 | $15.89 | -0.15% |
| Jul 19 | $13.51 | $14.70 | $15.98 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.51 | $14.70 | $15.98 | -0.17% |
| Week 2 | $13.03 | $14.67 | $16.52 | -0.34% |
| Week 3 | $12.66 | $14.65 | $16.94 | -0.51% |
| Week 4 | $12.36 | $14.62 | $17.29 | -0.68% |
| Week 5 | $12.10 | $14.60 | $17.61 | -0.84% |
| Week 6 | $11.86 | $14.57 | $17.90 | -1.01% |
| Week 7 | $11.65 | $14.55 | $18.17 | -1.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc.
in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EyePoint, Inc. (EYPT) is a healthcare stock with a current price of $14.44 and a market cap of $1.21B. It is ranked 2405 by market cap.
The stock trades with a technical backdrop described as BULLISH, with a current RSI14 of 60 and moving averages showing SMA50 at $13.18 and SMA200 at $14.14. Key support is listed at $11.45 and resistance at $14.44. The 30-day range spans from $11.62 to $17.94, and annualized volatility stands at 60%.
The multi-year forecast shows upside potential, with the 2026 avg price expected at $14.44 and a 2030 avg of $22.78, rising to a 2050 avg of $84.74. Max forecasts reach $34.53 by 2030, $90.56 by 2040, and $168.69 by 2050, with ROIs progressing to 57.8 by 2030 and 486.9 by 2050, indicating a strong long‑term upside despite near-term volatility.
A major floor 30.2% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 24.5% above — clearing it would confirm fresh momentum.
Key EYPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EYPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.41 | Buy | $14.44 | Buy |
| MA 10 | $14.13 | Buy | $14.19 | Buy |
| MA 20 | $13.74 | Buy | $13.83 | Buy |
| MA 50 | $13.23 | Buy | $13.57 | Buy |
| MA 100 | $13.92 | Buy | $13.69 | Buy |
| MA 200 | $14.15 | Buy | $13.38 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.39 | Neutral |
| Stoch RSI (14) | 73.69 | Neutral |
| CCI (20) | 112.33 | Buy |
| Williams %R (14) | -7.32 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 2.36 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 92.68 | Sell |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 1.12 | Buy |
| Ultimate (7,14,28) | 56.65 | Neutral |
| Momentum (10) | 1.01 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 14.62 | Buy |
| ADX (14) | 14.25 | Neutral |
| ATR (14) | 0.42 | Info |
Near term, the technical picture remains tilted toward bullish sentiment with a 30-day range of $11.62 to $17.94. The current price of $14.44 sits near the listed resistance level of $14.44, suggesting a potential test of that level in the near term. RSI(14) at 60 indicates room to move higher, while the SMA50 of $13.18 and SMA200 of $14.14 place the stock around a positive moving-average backdrop.
Support is noted at $11.45, providing a downside anchor if prices retreat, while a break above the $14.44 resistance could target higher levels within the 30-day range. The stock’s 30-day volatility is implicit in the broad range, underscoring a potential for sizeable swings in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.45 | $14.72 | $17.90 | 0% | Neutral | |
| $12.44 | $15.86 | $21.51 | +8% | Neutral | |
| $12.93 | $17.05 | $24.11 | +16% | Neutral | |
| $12.71 | $17.22 | $25.16 | +17% | Neutral | |
| $16.04 | $22.27 | $33.45 | +51% | Bullish | |
| $18.16 | $25.77 | $39.65 | +75% | Bullish | |
| $18.90 | $27.40 | $43.06 | +86% | Bullish | |
| $20.42 | $30.18 | $48.36 | +105% | Bullish | |
| $18.74 | $28.22 | $46.02 | +92% | Bullish | |
| $19.40 | $29.75 | $49.32 | +102% | Bullish | |
| $29.03 | $48.33 | $85.81 | +228% | Bullish | |
| $41.19 | $79.23 | $155.31 | +438% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.45 | $14.72 | $17.41 | +0.00% |
| August 2026 | $11.95 | $14.16 | $17.28 | -3.81% |
| September 2026 | $12.05 | $14.40 | $17.80 | +1.69% |
| October 2026 | $12.08 | $14.54 | $18.17 | +0.98% |
| November 2026 | $11.63 | $14.09 | $17.76 | -3.11% |
| December 2026 | $11.56 | $14.08 | $17.90 | -0.05% |
Click any year to see its month-by-month EYPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, EYPT is projected to trade between $11.45 and $17.90, averaging $14.72 — a potential gain of 0% from today's $14.72. A consolidation phase looks the most probable path here.
EyePoint, Inc.'s 2027 outlook centres on $15.86, within a $12.44 to $21.51 range. That is up +8% on the projected 2026 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2028, EYPT could reach as high as $24.11, with a base case around $17.05 and support toward $12.93 — roughly +16% from $14.72. A consolidation phase looks the most probable path here.
Expect EYPT to range from $12.71 to $25.16 through 2029. The $17.22 average target implies a +17% move from current prices. That is up +1% on the projected 2028 average. Price action looks broadly range-bound.
The EYPT price prediction for 2030 points to an average of $22.27 (low $16.04, high $33.45) — a potential gain of +51% on today's $14.72. Buyers look set to stay in control over this stretch.
In 2031, EYPT is projected to trade between $18.16 and $39.65, averaging $25.77 — a potential gain of +75% from today's $14.72. That is up +16% on the projected 2030 average. Momentum favours further upside here.
EyePoint, Inc.'s 2032 outlook centres on $27.40, within a $18.90 to $43.06 range. That is up +6% on the projected 2031 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, EYPT could reach as high as $48.36, with a base case around $30.18 and support toward $20.42 — roughly +105% from $14.72. Momentum favours further upside here.
Expect EYPT to range from $18.74 to $46.02 through 2034. The $28.22 average target implies a +92% move from current prices. That is -7% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The EYPT price prediction for 2035 points to an average of $29.75 (low $19.40, high $49.32) — a potential gain of +102% on today's $14.72. Momentum favours further upside here.
In 2040, EYPT is projected to trade between $29.03 and $85.81, averaging $48.33 — a potential gain of +228% from today's $14.72. That is up +62% on the projected 2035 average. Buyers look set to stay in control over this stretch.
EyePoint, Inc.'s 2050 outlook centres on $79.23, within a $41.19 to $155.31 range. That is up +64% on the projected 2040 average. That marks a +438% change versus current levels. Momentum favours further upside here.
Investing $1,000 in EYPT today (≈ 67.934783 EYPT) could be worth
$5,382.25
+$4,382.25 (+438%) by 2050 · US Dollar
Based on the average projected EYPT price of $79.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EYPTwould be worth at today's price.
$1,000 invested in EYPT on Jul 10, 2025 (≈ 90.41591 EYPT) would be worth
$1,330.92
+$330.92 (+33.1%) today · 1.33× · US Dollar
Based on a EYPT entry price of $11.06 vs. today's $14.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.98 | $1,052.93 | +5.3% |
| 1 month ago | $12.33 | $1,193.84 | +19.4% |
| 3 months ago | $14.19 | $1,037.35 | +3.7% |
| 6 months ago | $15.94 | $923.46 | -7.7% |
| 1 year ago | $11.06 | $1,330.92 | +33.1% |
| All time (5.0y) ago | $7.62 | $1,931.76 | +93.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EYPT forecast.
Our base-case forecast reaches $29.00 around 2033.
Implied market cap at $29.00: $2.43B
The multi-year forecast shows a clear path of elevated prices and expanding ROIs from 2026 through 2050. In 2030, the average price is forecast at $22.78 with a max of $34.53 and a ROI of 57.8, suggesting meaningful upside as the cadence of product development and potential commercial milestones could act as catalysts. By 2040, the average is $50.34 with a max of $90.56 and a ROI of 248.6, pointing to substantial long-term appreciation if trajectories hold.
By 2050, the average is $84.74 with a max of $168.69 and a ROI of 486.9, signaling substantial long‑term appreciation under the given assumptions. The forecast underscores bullish sentiment from 2029 onward, aligned with the progression of the lead DURAVYU program in Phase 3 for wet AMD and DME and the pre-clinical EYP-2301 program in the pipeline. While these projections imply strong upside, they are estimates and carry inherent uncertainty and risks, including market volatility (60% annualized) and clinical/pipeline outcomes that could diverge from the forecast.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $22.78 with a max of $34.53 and a ROI of 57.8, indicating potential upside from current levels.
The long-range forecast points to rising averages from $14.44 in 2026 to $84.74 in 2050, with ROIs reaching 486.9 by 2050 and sentiment turning bullish from 2029 onward. Near term, some years show neutral sentiment while volatility remains high.
Yes. The forecast maximum for 2033 is $50.23, with higher maxima of $90.56 by 2040 and $168.69 by 2050 as the horizon extends.
Current price is $14.44 and market cap is $1.21B, with a market rank of 2405.
The 30-day range is from $11.62 to $17.94.
EyePoint, Inc. Community Discussion
0Share your EyePoint, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.